Cowen and Company’s Agios Pharmaceuticals AGIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-30,000
Closed -$14K 660
2022
Q2
$14K Hold
30,000
﹤0.01% 443
2022
Q1
$24K Buy
30,000
+9,800
+49% +$299K ﹤0.01% 411
2021
Q4
$40K Buy
+20,200
New +$813K ﹤0.01% 456
2021
Q3
Sell
-68,100
Closed -$155K 576
2021
Q2
$155K Buy
68,100
+47,200
+226% +$2.64M 0.01% 299
2021
Q1
$137K Buy
20,900
+10,900
+109% +$540K 0.01% 297
2020
Q4
$63K Buy
+10,000
New +$395K 0.01% 249
2020
Q1
Sell
-5,000
Closed -$42K 410
2019
Q4
$42K Buy
+5,000
New +$189K ﹤0.01% 325

Other funds holding AGIO

Cowen and Company's AGIO Position: Q3 2022 in Review

Cowen and Company sold out of Agios Pharmaceuticals (AGIO) in Q3 2022, closing a stake of 27,132 shares — an estimated $602K sold.

Cowen and Company first reported a position in AGIO in Q3 2019 and held it in 4 quarters. The position peaked at $902K in Q3 2019. 169 funds tracked by Wall St. Rank hold AGIO as of Q3 2022.

  • Cowen and Company reported no remaining Agios Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Cowen and Company sold 27,132 Agios Pharmaceuticals shares in Q3 2022, an estimated $602K.
  • Cowen and Company first reported a position in Agios Pharmaceuticals in Q3 2019 and held it in 4 quarters.
  • Cowen and Company's Agios Pharmaceuticals position peaked at $902K in Q3 2019.
  • 169 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2022.

Based on Cowen and Company's 13F filing for Q3 2022, filed 14 Nov 2022.